Stay updated with breaking news from Sci Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome - Initial Draw of $20 Million to Support Funding Phase 3 Development... | June 30, 2022
• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated • Significant improvements were... | June 28, 2022
Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatmentCompany remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation -Additional analyses to... | June 21, 2022
13.06.2022 - RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO ...